

## ABCs Publications (by pathogen)

### Bacterial meningitis

Schuchat A, Robinson KA, Wenger JD, Harrison LH, Farley MM, Reingold AL, Lefkowitz L, Perkins BA and the Active Surveillance Team. Bacterial meningitis in the United States in 1995. *N Engl J Med* 1997;337:970-976.

Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. *J Infect Dis* 1990;162:1316-1323.

### Group A streptococcus

Robinson KA, Rothrock G, Phan Q, Sayler B, Stefonek K, Van Beneden C, Levine OS, for the Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Risk of severe group A streptococcal disease among patients' household contacts. *Emerg Infect Dis* 2003 *in press*.

Espinosa LE, Li Z, Rodriguez RS, Facklam R, Beall B. M-protein gene type distribution within group A streptococcal clinical isolates recovered in Mexico during years 1991-2000: Overlap with type distribution within the United States. *J. Clin Microbiol* 2003;41:373-378.

Chuang I, Van Beneden C, Beall B, Schuchat A and the ABCs/EIP Network. Population-based surveillance for postpartum invasive group A streptococcal infections, 1995-2000. *Clin Infect Dis* 2002;35:665-670.

Facklam RF, Martin DR, Lovgren M, Johnson DR, Efstraiou A, Thompson TA, Gowan S, Kriz P, Tyrrell GJ, Kaplan E, and Beall B. Extension of the classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: *emm*103 to *emm*104. *Clin Infect Dis* 2002;34:28-38.

Hu MC, Walls MA, Stroop S, Reddish M, Beall B, and Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. *Infect Immun* 2002;70:2171-2177.

O'Brien K, Beall B, Barrett NL, Cieslak, Ringold A, Farley MM, Danila, Zell ER, Facklam R, Schwartz B, Schuchat A. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. *Clin Infect Dis* 2002;35:268-276.

The Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case-patients and among postpartum and post-surgical patients: Recommendations from the Centers for Disease Control and Prevention. *Clin Infect Dis* 2002;35:950-959.

Centers for Disease Control and Prevention. Provisional 2001. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus, Provisional 2001. Available via the Internet: [http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas01\\_provis.pdf](http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas01_provis.pdf).

Stefonek KR, Maerz LL, Nielson MP, Besser RE, Cieslak PR. Group A streptococcal puerperal sepsis preceded by positive surveillance cultures. *Obstet Gynecol* 2001;98:846-

848.

Centers for Disease Control and Prevention. 2000. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas00.pdf>.

Beall B, Gherardi G, Facklam R, and Hollingshead S. Pneumococcal *psp A* sequence types of prevalent multi-resistant strains in the United States and of internationally disseminated pneumococcal clones. *J Clin Microbiol* 2000;38:3663-3669.

Beall B, Gherardi G, Lovgren M, Forwick B, Facklam R, and Tyrrell G. *emm* and *sof* gene sequence variation in relation to serological typing of opacity factor positive group A streptococci. *Microbiology* 2000;146:1195-1209.

Centers for Disease Control and Prevention. 1999. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas99.pdf>.

Facklam R, Beall B, Efstratiou A, Fischetti V, Johnson D, Kaplan E, Kriz P, Lovgren M, Martin D, Schwartz B, Totolian A, Bessen D, Hollingshead S, Rubin F, Scott J, Tyrrell, G. Demonstration of *emm* typing and validation of provisional M types for group A streptococci. *Emerg Infect Dis* 1999;5:247-53.

Hoe NP, Nakashima K, Lukomski S, Grigsby D, Liu M, Kordari P, Dou SJ, Pan X, Vuopio-Varkila J, Salmenlinna S, McGeer A, Low DE, Schwartz B, Schuchat A, Naidich S, DeLorenzo D, Yun-Xin F, Musser JM. Rapid selection of structural variants of group A streptococcus complement-inhibiting protein sustains and enlarges serotype M1 epidemic waves. *Nat Med* 1999;5:924-929.

York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in *Streptococcus pyogenes* isolates from the San Francisco Bay area of Northern California. *J Clin Microbiol* 1999;37(6):1727-1731.

Beall B, Facklam RR, Jackson DM, Starling HH. Rapid screening of penicillin-susceptibility in systemic pneumococcal isolates by restriction enzyme profiling of the *php 2B* gene. *J Clin Microbiol* 1998;36:2359-2362.

Centers for Disease Control and Prevention. 1998. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas98.pdf>.

Beall B, Facklam R, Elliott JA, Franklin AR, Hoenes T, Jackson D, La Claire L, Thompson T, Viswanathan R. Streptococcal *emm* types associated with T agglutination patterns and the use of conserved *emm* gene restriction fragment patterns for subtyping group A streptococci. *J Med Microbiol* 1998;47:893-898.

The Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive group A streptococcal disease among household contacts of case-patients. *JAMA* 1998;279:1206-1210.

Zurawski CA, Bardsley M, Beall B, Elliott JA, Facklam RR, Schwartz B, Farley M. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment.

Clin Infect Dis 1998;27:150-157.

Centers for Disease Control and Prevention. 1997. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas97.pdf>.

Beall B, Facklam R, Hoenes T, Schwartz B. A survey of *emm* gene sequences from systemic *Streptococcus pyogenes* infection isolates collected in San Francisco, California; Atlanta, Georgia; and Connecticut in 1994 and 1995. J Clin Microbiol 1997;35:1231-1235.

Fiorentino TR, Beall B, Mshar P, Bessen DE. A genetic-based evaluation of principal tissue reservoir for group A streptococci isolated from normally sterile sites. J Infect Dis 1997;176:177-182.

Beall B, Facklam R, Thompson T. Sequencing *emm*-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996;34:953-958.

### **Group B streptococcus**

*1998 to present:*

Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. MMWR Morb Mortal Wkly Rep 2002;51(No.RR-11):1-22.

Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig A, Harrison LH, Reingold A, Stefonek K, Smith G, Gamble M, Schuchat A. A population-based comparison of strategies to prevent early onset group B streptococcal disease in neonates. New Engl J Med 2002;347:233-9.

Schuchat A, Roome A, Zell ER, Linardos H, Zywicki S, O'Brien KL. Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections. Maternal Child Health J 2002;6(2):107-114.

Centers for Disease Control and Prevention. Provisional 2001. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, Provisional 2001. Available via the Internet: [http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs01\\_provis.pdf](http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs01_provis.pdf).

Henning KJ, Hall EL, Dwyer DM, Billmann L, Schuchat A, Johnson JA, Harrison LH. Invasive group B streptococcal disease in Maryland nursing home residents. J Infect Dis 2001;183:1138-1142.

Schuchat A. Group B streptococcal infections: from trials and tribulations to triumph and trepidation. Clin Infect Dis 2001;33:751-756.

Baltimore RS, Huie SM, Meek JI, Schuchat A, O'Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics 2001;108(5):1094-1098.

Centers for Disease Control and Prevention. 2000. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs00.pdf>.

Centers for Disease Control and Prevention. Hospital-based policies for prevention of

perinatal group B streptococcal disease, United States 1999. MMWR Morb Mortal Wkly Rep 2000; 49 (41):936-940.

Centers for Disease Control and Prevention. Early-onset group B streptococcal disease, United States, 1998-1999. MMWR Morb Mortal Wkly Rep 2000;49:793-796.

Centers for Disease Control and Prevention. Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers- Connecticut and Minnesota. MMWR Morb Mortal Wkly Rep 2000; 49(11):228-232.

Factor SH, Whitney CG, Zywicki SS, Schuchat A for the Active Bacterial Core Surveillance Team. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. Obstet Gynecol 2000;95:377-382.

Hager WD, Schuchat A, Gibbs R, Sweet R, Mead P, Larsen JW. Prevention of perinatal group B streptococcal infection: addressing current controversies. Obstet Gynecol 2000;96:141-145.

Schrag S, Whitney CG, Schuchat A. Neonatal group B streptococcal disease: How infection control teams can contribute to prevention efforts Infect Control Hosp Epidemiol 2000:473-483.

Schrag SJ, Zywicki S, Farley M, Reingold A, Harrison L, Lefkowitz L, Hadler J, Danila R, Cieslak P, Schuchat A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20.

Schuchat A, Schrag S. Group B Streptococcus: from emerging infection to prevention success story. In: Scheld WM, Craig WA, Hughes JM. *Emerging Infections 4*. Washington, DC: American Society for Microbiology; 2000:107-120.

Centers for Disease Control and Prevention. 1999. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs99.pdf>.

Centers for Disease Control and Prevention. Laboratory practices for prenatal group B streptococcal screening and reporting. MMWR Morb Mortal Wkly Rep 1999;48:426-428.

Centers for Disease Control and Prevention. 1998. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs98.pdf>.

Centers for Disease Control and Prevention. Adoption of hospital policies for prevention of perinatal group B streptococcal disease – United States, 1997. MMWR Morb Mortal Wkly Rep 1998;47:665-670.

Harrison LH, Elliot JA, Libonati JP, Billmann L, Schuchat A, Dwyer DM, and the Maryland Bacterial Invasive Disease Surveillance Group. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. J Infect Dis 1998;177:998-1002.

Wessels MR, Kasper DL, Johnson KD, Harrison LH. Antibody responses in invasive group B streptococcal infection in adults. J Infect Dis 1998;178:569-572.

**1995 - 1997:**

Centers for Disease Control and Prevention. 1997. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs97.pdf>.

Centers for Disease Control and Prevention. Decreasing incidence of perinatal group B streptococcal disease -- United States, 1993-1995. MMWR Morb Mortal Wkly Rep 1997;46:473-477.

Rosenstein NE, Schuchat A, and the Neonatal Group B Streptococcal Disease Study Group. Opportunities for prevention of perinatal group B streptococcal disease: a multi-state surveillance analysis. Obstet Gynecol 1997;90:901-906.

Whitney C, Plikaytis BD, Gozansky W, Schuchat A, Neonatal group B streptococcal disease study group. Prevention practices for perinatal group B streptococcal disease: a multistate surveillance analysis. Obstet Gynecol 1997;89:28-32.

Blumberg HM, Stephens DS, Modansky M, Erwin M, Elliott J, Facklam RR, Schuchat A, Baughman W, Farley MM. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996;173:365-373.

Jackson L, Farley M, Schuchat A. Adult group B streptococcal disease. Ann Int Med 1996;125:152-153.

Schuchat A, Whitney C, Zangwill K. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Morb Mortal Wkly Rep 1996;45 (RR-7):1-24.

Harrison LH, Ali A, Dwyer DM, et al. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med 1995;123:421-427.

Jackson L, Hilsdon R, Farley M, Harrison L, Reingold A, Wenger JD, Schuchat A. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995;123:415-420.

**1992 - 1994:**

Schuchat A, Deaver-Robinson K, Plikaytis BD, Zangwill KM, Mohle-Boetani J, Wenger JD. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. Pediatr Infect Dis J 1994;13:623-629.

Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, Stephens DS. A population-based assessment of invasive disease due to group B streptococcus in nonpregnant adults. N Engl J Med 1993;328:1807-1811.

Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal group B streptococcal infection: A population-based economic analysis. JAMA 1993;270:1442-1448.

Zangwill KM, Schuchat A, Wenger JD, and the Group B Streptococcal Disease Study Group. Group B streptococcal disease in the United States: Report from a multistate active surveillance system. MMWR Morb Mortal Wkly Rep 1992; 41 [No. SS-6]:25-32.

### ***Haemophilus influenzae***

#### **1998 - present:**

LaClaire LL, Tondella MLC, Beall DS, Nobel CA, Raghunathan PL, Rosenstein NE, Popovic T, and the ABCs Team Members. Identification of *Haemophilus influenzae* serotypes by standard slide agglutination serotyping and PCR-based capsule typing. *J Clin Microbiol* 2003;41:1:393-396.

Ohuabunwo C, Bath S, Bisgard K, Murphy T, Shutt K, Rosenstein N. Progress Toward Elimination of *Haemophilus influenzae* Type b Invasive Disease Among Infants and Children, United States, 1998--2000. *MWR Morb Mortal Wkly Rep* 2002; 51(11); 234-237.

Raghunathan PL, LaClaire LL, Tondella ML, Beall DS, Noble CS, Rosenstein NE, Popovic T. Serotyping discrepancies in *Haemophilus influenzae* type b disease, United States, 1998—1999. *MMWR Morb Mortal Wkly Rep* 2002;51(32):706-707.

Centers for Disease Control and Prevention. Provisional 2001. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, Provisional 2001. Available via the Internet: [http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib01\\_provis.pdf](http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib01_provis.pdf).

Centers for Disease Control and Prevention. 2000. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib00.pdf>.

Centers for Disease Control and Prevention. 1999. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib99.pdf>.

Centers for Disease Control and Prevention. Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended for Children – United States, 1990-1999. *MMWR Morb Mortal Wkly Rep* 1999;48:243-248.

Jafari HS, Adams WG, Robinson KA, Plikaytis BD, Wenger JD. Efficacy of *Haemophilus influenzae* type b conjugate vaccines and persistence of disease in disadvantaged populations. The *Haemophilus Influenzae* Study Group. *Am J Public Health* 1999;89:364-368.

Centers for Disease Control and Prevention. 1998. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib98.pdf>.

Bisgard K, Kao A, Leake J, Strebler PM, Perkins BA, Wharton M. *Haemophilus influenzae* disease in the United States, 1994-1995: Near disappearance of a vaccine-preventable childhood disease. *Emerg Infect Dis* 1998;4:229-237.

Centers for Disease Control and Prevention. Progress Toward Elimination of *Haemophilus influenzae* Type b Disease Among Infants and Children -- United States, 1987-1997. *MMWR Morb Mortal Wkly Rep* 1998;47:993-998.

#### **1995 - 1997:**

Centers for Disease Control and Prevention. 1997. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Haemophilus influenzae*, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib97.pdf>.

Centers for Disease Control and Prevention. Progress Toward Elimination of *Haemophilus influenzae* type b disease among infants and children -- United States, 1987-1995. MMWR Morb Mortal Wkly Rep 1996;45:901-906.

Urwin G, Krohn JA, Deaver-Robinson K, Wenger JD, Farley MM, and the *H. Influenzae* study group. Invasive *Haemophilus influenzae* serotype f disease: Clinical and epidemiological characteristics in the Hib vaccine era. Clin Inf Dis 1996;22:1069-1076.

Centers for Disease Control and Prevention. Progress toward elimination of *Haemophilus influenzae* Type b disease among infants and children—United States, 1993-1994. MMWR Morb Mortal Wkly Rep 1995;44:545-550.

**1992 - 1994:**

Centers for Disease Control and Prevention. Progress Toward elimination of *Haemophilus influenzae* type b disease among infants and children -- United States, 1987-1993. MMWR Morb Mortal Wkly Rep 1994;43:144-148.

Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD. Decline of childhood *Haemophilus influenzae* Type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-226.

Wenger JD, Pierce R, Deaver K, Franklin R, Bosley G, Pigott N, Broome CV. Invasive *Haemophilus influenzae* disease: A population-based evaluation of the role of capsular polysaccharide serotype. J Infect Dis 1992;165 [Suppl. 1]:S34-35.

**1988 - 1991:**

Wenger JD, Pierce R, Deaver KA, Plikaytis BD, Facklam RR, Broome CV, and the *Haemophilus influenzae* Vaccine Efficacy Study Group. Efficacy of *Haemophilus influenzae* type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Lancet 1991;338:395-398.

Wenger JD, Harrison LH, Hightower A, Broome CV. Day care characteristics associated with *Haemophilus influenzae* disease. Am J Public Health 1990;80:1455-8.

Harrison LH, Broome CV, Hightower AW. *Haemophilus influenzae* type b polysaccharide vaccine: an efficacy study. Pediatrics 1989;84:255-61.

Harrison LH, Broome CV, Hightower AW, Hoppe CC, Makintubee S, Sitze SL, Taylor JA, Gaventa S, Wenger JD. A day care-based study of the efficacy of *Haemophilus* b polysaccharide vaccine. JAMA 1988;260:1413-1418.

### ***Neisseria meningitidis***

**1998 to present:**

Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990-1999. Pediatr Infect

Dis J, 2003;22:418-22.

Centers for Disease Control and Prevention. Provisional 2001. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, Provisional 2001. Available via the Internet: [http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening01\\_provis.pdf](http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening01_provis.pdf).

Finn R, Groves C, Coe M, Pass M, Harrison LH. A cluster of serogroup C meningococcal disease associated with attendance at a party. South Med J. 2001;94(12):1192-1194.

Harrison LH, Pass MA, Mendelsohn AB, Egri M, Pass M, Rosenstein NE, Razeq J, Roche JC. Invasive meningococcal disease in adolescents and young adults. JAMA 2001;286:694-699.

Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA and the Active Bacterial Core Surveillance (ABCs) Team. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine 2001;19(31):4566-4575.

Popovic T, Schmink S, Rosenstein NA, Ajello GW, Reeves MW, Plikaytis B, Hunter SB, Ribot EM, Boxrud D, Tondella ML, Kim C, Noble C, Mothershed E, Besser J, Perkins BA. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of Meningococcal disease outbreaks caused by *Neisseria meningitidis* serogroup C. J Clin Microbiol 2001;39(1):75-85.

Centers for Disease Control and Prevention. 2000. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening00.pdf>.

Rosenstein NE, Stocker SA, Popovic T, Tenover FC, Perkins BA, and the Active Bacterial Core Surveillance Team. Antimicrobial resistance of *Neisseria meningitidis* in the United States, 1997. Clin Infect Dis 2000;30:212-213.

Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, Rosenstein NE, Perkins BA, Tondella MLC, Mayer LW. Diversity and prevalence of PorA types in *Neisseria meningitidis* serogroup B in the United States, 1992-1998. J Infect Dis 2000;182:1169-1176.

Tondella M, Popovic T, Rosenstein N, Lake D, Carlone G, Perkins B. Distribution of *Neisseria meningitidis* serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol 2000;38:3323-3328.

Centers for Disease Control and Prevention. 1999. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening99.pdf>.

Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, Fleming D. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA. 1999;281(16):1493-1497.

Harrison LH, Dwyer DM, Maples CT, Billmann L. The risk of meningococcal infection in college students. JAMA 1999;281:1906-1910.

Rosenstein NE, Perkins BA, Stephens D, Lefkowitz L, Carter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL, and the Active Bacterial Core Surveillance Team. The changing epidemiology of meningococcal disease in the United States, 1992-1996. *J Infect Dis* 1999;180:1894-1901.

Yusuf HR, Rochat RW, Baughman WS, Gargiullo PM, Perkins BA, Brantley MD, Stephens DS. Maternal cigarette smoking and invasive meningococcal disease: a cohort study among young children in metropolitan Atlanta, 1989-1996. *Am J Public Health* 1999;89:712-717.

1995 - 1997:

Centers for Disease Control and Prevention. 1998. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening98.pdf>.

Centers for Disease Control and Prevention. 1997. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening97.pdf>.

Centers for Disease Control and Prevention. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 1997;46 (No. RR-5):1-10.

Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 1997;46 (No. RR-5):13-21.

Fischer M, Hedberg K, Cardosi P, Plikaytis BD, Hoesly FC, Steingart KR, et al. Tobacco smoke as a risk factor for meningococcal disease. *Pediatr Infect Dis J* 1997;16:979-983.

Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD, Stephens DS. Capsule switching of *Neisseria meningitidis*. *Proc Natl Acad Sci* 1997; 94:271-276.

Zangwill K, Schuchat A, Riedo FX, Pinner RW, Koo DT, Reeves MW, Wenger JD. School-based clusters of meningococcal disease in the United States: descriptive epidemiology and a case-control analysis. *JAMA* 1997;277:389-395.

Centers for Disease Control and Prevention. Serogroup Y meningococcal disease--Illinois, Connecticut, and selected areas, United States, 1989-1996. *MMWR Morb Mortal Wkly Rep* 1996;45:1010-1013.

Centers for Disease Control and Prevention. Serogroup B Meningococcal Disease -- Oregon 1994. *MMWR Morb Mortal Wkly Rep* 1995;44:121-124.

Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: An emerging threat. *JAMA* 1995;273:383-389.

Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. *Am J Public Health* 1995;85:843-845.

Reeves MW, Perkins BA, Diermayer M, Wenger JD. Epidemic-associated *Neisseria*

*meningitidis* detected by multilocus enzyme electrophoresis. *Emerg Infect Dis* 1995;1:53-54.

Stephens DS, Hajjeh RA, Baughman WS, Harvey CH, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. *Ann Intern Med* 1995;123:937-940.

**1992 - 1994:**

Jackson LA, Tenover FC, Baker C, Plikaytis BD, Reeves MW, Stocker SA, Weaver RE, Wenger JD, and the Meningococcal Disease Study Group. Prevalence of *Neisseria meningitidis* relatively resistant to penicillin in the United States, 1991. *J Infect Dis* 1994;169: 338-341.

Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected counties, United States, 1989-1991. *MMWR Morb Mortal Wkly Rep* 1993;42:21-30.

**1988 - 1991:**

Pinner RW, Gellin BG, Bibb WF, Baker CN, Weaver R, Hunter SB, Waterman SH, Mocca LF, Frasch CE, Broome CV, and the Meningococcal Disease Study Group. Meningococcal disease in the United States - 1986. *J Infect Dis* 1991;164:368-374.

### ***Streptococcus pneumoniae***

**1998-present:**

Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgenson JH, and Schuchat A for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med* 2003;348:1737-46.

Dowell SF, Whitney CG, Wright C, Rose CE, and Schuchat A. Seasonal patterns of invasive pneumococcal disease. *Emerg Infect Dis* 2003;9(5): 573-579.

Albanese BA, Roche JC, Pass M, Whitney CG, McEllistrem MC, Harrison LH. Geographic, demographic, and seasonal differences in penicillin-resistant *Streptococcus pneumoniae* in Baltimore. *Clin Infect Dis* 2002;34(1):15-21.

Beall B, McEllistrem MC, Gertz RE Jr, Boxrud DJ, Besser JM, Harrison LH, Jorgenson JH and Whitney CG, for the Active Bacterial Core Surveillance/ Emerging Infections Program Network.. Emergence of a novel penicillin resistant clone of serotype 35B *Streptococcus pneumoniae* in the United States. *J Infect Dis* 2002;186:118-122

Braum SE, Crawford SA, McEmee ML, Whitney CG, Jorgensen JH. Comparative activities of the oxazolidinone AZD2563 and linzolid against selected recent North American isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2002;46(9):3094-3095.

Centers for Disease Control and Prevention. Assessment of Susceptibility Testing Practices for *Streptococcus pneumoniae* – United States, February 2000. *MMWR Morb*

Mortal Wkly Rep 2002;51(18):392-4.

Fry AM, Zell ER, Schuchat A, Butler JC Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002;21:303-311.

McEllistrem MC, Mendelsohn AB, Pass MA, Elliott JA, Whitney CG, Kolano JA, Harrison LH. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J Infect Dis 2002;185:1364-1368.

McEllistrem MC, Mendelsohn AB, Elliott JA, Whitney CG, Albanese BA, Harrison LH. Distribution of penicillin-nonsusceptible pneumococcal clones in the Baltimore metropolitan area and variables associated with drug resistance. Clin Infect Dis 2002;34(5):704-707

Morita JY, Zell ER, Danila R, Farley MM, Hadler J, Harrison LH, Lefkowitz L, Reingold A, Kupronis BA, Schuchat A, Whitney CG. Association between antimicrobial resistance among pneumococcal isolates and burden of invasive pneumococcal disease in the community. Clin Infect Dis 2002;35:420-427.

Schrag SJ, Zell E, Schuchat A, Whitney CG. Evaluation of sentinel surveillance for drug-resistant *Streptococcus pneumoniae*. Emerg Inf Dis 2002;8(5):496-502.

Shelvin JD. Summers-Bean C. Thomas D. Whitney CG. Todd D. Ray SM. A symptomatic approach for increasing pneumococcal vaccination rates at an inner-city hospital. Am J Prev Med 2002;22(2):92-97.

Centers for Disease Control and Prevention. Provisional 2001. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, Provisional 2001. Available via the Internet: [http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu01\\_provis.pdf](http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu01_provis.pdf).

Ehresmann KR. Ramesh A. Como-Sabetti K. Peterson DC. Whitney CG. Moore KA. Factors associated with self-reported pneumococcal immunization among adults 65 years of age or older in the Minneapolis-St. Paul metropolitan area. Prev Med 2001;32(5):409-415.

Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, Barrett NL, Schaffner W, Cieslak PR, Maupin PS, Zell ER, Jorgensen JH, Facklam RR, Whitney CG. Active Bacterial Core Surveillance/Emerging Infections Program Network. Macrolide resistance among invasive *Streptococcus pneumoniae* isolates. JAMA 2001;286(15):1857-1862.

Moroney JF, AE. Fiore, LH Harrison, JE. Patterson, M Farley, JH. Jorgensen, M Phelan, RR. Facklam, MS Cetron, RF Breiman, M Kolczak, A Schuchat. Clinical outcomes of invasive pneumonia caused by *Streptococcus pneumoniae* in the era of antibiotic resistance. Clin Infect Dis 2001;33:797-805.

Robinson K, Baughman W, Rothrock G, Barrett N, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell E, Schuchat A, Whitney C. Epidemiology of *Streptococcus pneumoniae* infections in the U.S., 1995-1998 – Opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729-1735.

Centers for Disease Control and Prevention. Resistance of *Streptococcus pneumoniae* to Fluoroquinolones ---United States, 1995--1999. MMWR Morb Mortal Wkly Rep 2001;50(37):800-804.

Breiman RF, Keller DW, Phelan M, Sniadack D, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold A. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med. 2000;160:2633-2638.

Centers for Disease Control and Prevention. 2000. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2000. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu00.pdf>.

Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(No.RR-9):1-35.

Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-229.

Fiore AE, Moroney JF, Farley MM, Harrison LH, Patterson JE, Jorgensen M, Kolczak MS, Breiman RF, Schuchat A. Clinical outcomes of meningitis caused by *Streptococcus pneumoniae* in the era of antibiotic resistance. Clin Infect Dis 2000;30:71-77.

Gay K, Baughman W, Miller Y, Jackson D, Whitney CG, Schuchat A, Farley MM, Tenover F, Stephens DS. The emergence of *Streptococcus pneumoniae* resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000;182(5):1417-1424.

Gherardi G, Whitney CG, Facklam RR, Beall B. Major related sets of antibiotic-resistant pneumococci in the United States as determined by PFGE and *pbp1a-pbp2b-pbp2x-dhf* restriction profiles. J Infect Dis 2000;181:216-229.

Harrison LH, Dwyer DM, Billmann L, Kolczak MS, Schuchat A, and the Maryland Emerging Infections Program. Invasive pneumococcal infection in Baltimore: implications for immunization policy. Arch Intern. Med 2000;160 (1):89-94.

Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant *Streptococcus pneumoniae* therapeutic working group. Arch Intern Med 2000;160:1399-1408.

Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro MJ, Tenover FC. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant *Streptococcus pneumoniae*. Antimicrob Agents Chemother 2000;44:2962-2968.

McEllistrem MC, Pass M, Elliott JA, Whitney CG, Harrison LH. Clonal groups of penicillin-nonsusceptible *Streptococcus pneumoniae* in Baltimore, Maryland: A population-based,

molecular epidemiologic study. *J Clin Microbiol* 2000;38(12):4367-4372.

Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis* 2000;30:520-528.

Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF, and the Active Bacterial Core Surveillance Team. Cigarette smoking and invasive pneumococcal disease. *N Engl J Med* 2000;342:681-689.

Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. *Ann Intern Med* 2000;132:182-190.

Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A. Increasing prevalence of multidrug-resistant *Streptococcus pneumoniae* in the United States. *N Engl J Med* 2000;343:1917-1924.

Centers for Disease Control and Prevention. 1999. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1999. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu99.pdf>.

Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in *Streptococcus pneumoniae*- Selected Sites, United States, 1997. *MMWR Morb Mortal Wkly Rep* 1999;48:656-661.

Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B for the Active Bacterial Core Surveillance Team. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. *Pediatrics* 1999;103(3):e28.

Centers for Disease Control and Prevention. 1998. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1998. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu98.pdf>.

Butler JC, Dowell SF, Breiman RF. Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. *Vaccine* 1998;16:1693-1697.

Chen FM, Breiman RF, Farley M, Plikaytis B, Deaver K, Cetron MS. Geocoding and linking data from population-based surveillance and the US census to evaluate the impact of median household income on the epidemiology of invasive *Streptococcus pneumoniae* infections. *Am J Epidemiol* 1998;148:1212-1218.

#### 1995-1997:

Centers for Disease Control and Prevention. 1997. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 1997. Available via the Internet: <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu97.pdf>.

Centers for Disease Control and Prevention. Assessment of National Reporting of Drug-Resistant *Streptococcus pneumoniae* -- United States, 1995-1996. *MMWR Morb Mortal*

Wkly Rep 1996;45:947-959.

Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, Deaver KA, Breiman RF. The prevalence of drug-resistant *Streptococcus pneumoniae* in Atlanta. N Engl J Med 1995;333:481-486.

1988-1994:

Schuchat A, Broome CV, Hightower AW, Costa S, Parkin W. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. JAMA 1991;265:3275-3279.

### Other

CDC. HIV testing among pregnant women, United States and Canada, 1998-2001. MMWR Morb Mortal Wkly Rep 2002;51(45):1013-1016.

Hyde T, Hilger T, Reingold A, Farley MM, O'Brien, Schuchat A. Trends in incidence and antimicrobial resistance of early-onset sepsis: Population-based surveillance in San Francisco and Atlanta. Pediatrics 2002;110:690-695

Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, Lefkowitz L, Danila R, Stefonek K, Barrett N, Morse D and Pinner R, for the Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. Update from the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Emerg Infect Dis 2001;92-99.

Centers for Disease Control and Prevention. Laboratory capacity to detect antimicrobial resistance, 1998. MMWR Morb Mortal Wkly Rep 2000;48(51):1167-1171.